Skip to main content

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfille

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfille

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Study of Ruxolitinib in Colorectal Cancer Patients

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Study of Ruxolitinib in Colorectal Cancer Patients

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

The Chimerix CMX001 Registry

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about The Chimerix CMX001 Registry

A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 166
  • Page 167
  • Page 168
  • Page 169
  • Page 170
  • Page 171
  • Page 172
  • Page 173
  • Page 174
  • …
  • Next page Next
  • Last page Last
Subscribe to